SOURCE-LINKED STUDY SUMMARY
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
What was studied?
A randomized, double-blind human trial compared liraglutide with placebo. The primary outcome was time to type 2 diabetes by 160 weeks.
What changed?
Diabetes was diagnosed during treatment in 2% versus 6%. Weight fell 6.1 versus 1.9 percent at 160 weeks. Serious adverse events occurred in 15% versus 13%.
Who was studied?
2254 adults with prediabetes and obesity, or overweight with additional conditions, were randomized.
Studied exposure
Participants received subcutaneous liraglutide 3.0 mg or matched placebo daily, alongside reduced-calorie eating and increased activity.
What remains uncertain?
Participants who withdrew were not followed after stopping treatment, limiting interpretation of outcomes beyond continued treatment.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(17)30069-7